Disc Medicine Executive Compensation (FY25)
IRON · Executive and director compensation, fiscal 2023 to 2025
The Disc Medicine brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 21, 2026Latest filing (8-K): June 24, 2026
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
217 figures on this page: 215 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Quisel: $9,065,924 → $9,986,626 (10.2% higher)
CEO pay ratio: 20:1 → 18:1 (10.0% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Disc Medicine's chief executive and what were they paid?
Total compensation for John Quisel, President and Chief Executive Officer, came to $9,986,626 in fiscal 2025. Compared with the $9,065,924 reported for fiscal 2024, Quisel's total was 10.2% higher.
What was Disc Medicine's say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 98.9% support at the meeting held June 18, 2026.
Which companies are in Disc Medicine's peer group?
The disclosed peer group includes 89Bio, Inc., Akero Therapeutics, Inc., Calculation of Actual Bonus Payouts, Centessa Pharmaceuticals plc and Cogent Biosciences, Inc., among others.
What is Disc Medicine's chief executive pay ratio?
The company reported a chief executive pay ratio of 18:1 for fiscal 2025, against median employee compensation of $570,211.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Quisel President and Chief Executive Officer | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
William Savage Chief Medical Officer | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Jonathan Yu Chief Operating Officer | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Quisel President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jean Franchi Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | — | ◇ |
Pamela Stephenson Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
William Savage Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Yu Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Quisel President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jean Franchi Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Pamela Stephenson Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
William Savage Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Yu Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Jean Franchi | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jean Franchi | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Quisel | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John Quisel | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jonathan Yu | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jonathan Yu | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Pamela Stephenson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Pamela Stephenson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| William Savage | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| William Savage | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| John Quisel | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/10/2035 | |
| Option | ◇ | — | ◇ | 1/10/2034 | |
| Option | ◇ | — | ◇ | 12/29/2032 | |
| Pamela Stephenson | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/10/2035 | |
| Option | ◇ | — | ◇ | 2/25/2034 | |
| William Savage | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/10/2035 | |
| Option | ◇ | — | ◇ | 1/10/2034 | |
| Option | ◇ | — | ◇ | 12/29/2032 | |
| Jean Franchi | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/6/2034 | |
| Option | ◇ | — | ◇ | 2/10/2035 | |
| Jonathan Yu | Option | ◇ | — | ◇ | 12/29/2032 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/10/2035 | |
| Option | ◇ | — | ◇ | 1/10/2034 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Jean Franchi
Chief Financial Officer · Employment agreement · citing a 2024 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Pamela Stephenson
Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Change-in-control base | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Nadim Ahmed, M.S | ◇ | — | ◇ | — | — | — | ◇ |
Donald Nicholson, Ph.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Donald Nicholson | ◇ | — | ◇ | — | — | — | ◇ |
Georges Gemayel, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
William White, M.P.P., J.D | ◇ | — | ◇ | — | — | — | ◇ |
Kevin Bitterman | ◇ | — | ◇ | — | — | — | ◇ |
Kevin Bitterman, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Liam Ratcliffe, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Mark Chin, M.S., M.B.A | ◇ | — | ◇ | — | — | — | ◇ |
Mona Ashiya | ◇ | — | ◇ | — | — | — | ◇ |
Mona Ashiya, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
John Quisel, J.D., Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 89Bio, Inc. ETNB
- Akero Therapeutics, Inc. AKRO
- Calculation of Actual Bonus Payouts symbol not shown
- Centessa Pharmaceuticals plc CNTA
- Cogent Biosciences, Inc. COGT
- Cullinan Therapeutics, Inc. CGEM
- Dyne Therapeutics, Inc. DYN
- Edgewise Therapeutics, Inc. EWTX
- Fulcrum Therapeutics, Inc. FULC
- IDEAYA Biosciences, Inc. IDYA
- iTeos Therapeutics, Inc. ITOS
- Keros Therapeutics, Inc. KROS
- Kymera Therapeutics, Inc. KYMR
- Protagonist Therapeutics, Inc. PTGX
- Scholar Rock Holding Corporation SRRK
- Stoke Therapeutics, Inc. STOK
- Syndax Pharmaceuticals, Inc. SNDX
- Terns Pharmaceuticals, Inc. TERN
- Viridian Therapeutics, Inc. VRDN
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 18, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 11, 2025 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Disc Medicine disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Disc Medicine sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
217 figures on this page: 215 cited to the filing that reported them, 2 calculated from figures it prints.
215 cited to the filing
2 calculated from the filing
Documents cited
- 0001193125-26-281096
- 0001193125-26-1876462025 Summary Compensation Table · Compensation Discussion and Analysis · Grants of Plan-Based Awards · NON-EMPLOYEE DIRECTOR COMPENSATION
- 0000950170-25-086352
- 0000950170-25-0581422024 Summary Compensation Table
- 0000950170-24-0513762023 Summary Compensation Table
- 0001193125-24-025951EX-10.20
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Disc Medicine executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/IRON (accessed 2026).
Short form: data: Velarion
The Disc Medicine brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Disc Medicine and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Disc Medicine discloses
The companies named in IRON's own disclosed peer group.
89Bio, Inc.Akero Therapeutics, Inc.Cogent Biosciences, Inc.Cullinan Therapeutics, Inc.Dyne Therapeutics, Inc.Edgewise Therapeutics, Inc.Fulcrum Therapeutics, Inc.IDEAYA Biosciences, Inc.iTeos Therapeutics, Inc.Keros Therapeutics, Inc.Kymera Therapeutics, Inc.Protagonist Therapeutics, Inc.Scholar Rock Holding CorporationStoke Therapeutics, Inc.Syndax Pharmaceuticals, Inc.Terns Pharmaceuticals, Inc.Viridian Therapeutics, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}